Live Breaking News & Updates on Data Expected This Summer

Stay updated with breaking news from Data expected this summer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update

– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026. ....

Mike Andriole , Marcd Kozin , Patrick Machado , Oncology Consortium , Therapeutic Goods Administration , National Institutes Of Health , Company To Advance Dordaviprone , Exchange Commission , Company Board Of Directors , Reiterates Expectations , Interim Overall Survival , Preliminary Phase , Data Expected This Summer , Advance Dordaviprone , Conference Call , Chief Executive Officer , National Institutes , Pacific Pediatric Neuro Oncology Consortium , Chimerix Board , Private Securities Litigation Reform Act , Provisional Determination , Months Ended March ,